CRIS vs. CDTX, SABS, SGMO, AGEN, TVGN, TSBX, AVRO, IKNA, ATRA, and GNTA
Should you be buying Curis stock or one of its competitors? The main competitors of Curis include Cidara Therapeutics (CDTX), SAB Biotherapeutics (SABS), Sangamo Therapeutics (SGMO), Agenus (AGEN), Tevogen Bio (TVGN), Turnstone Biologics (TSBX), AVROBIO (AVRO), Ikena Oncology (IKNA), Atara Biotherapeutics (ATRA), and Genenta Science (GNTA). These companies are all part of the "medical" sector.
Curis (NASDAQ:CRIS) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.
Cidara Therapeutics has a net margin of -55.49% compared to Curis' net margin of -473.04%. Curis' return on equity of -169.22% beat Cidara Therapeutics' return on equity.
In the previous week, Curis had 1 more articles in the media than Cidara Therapeutics. MarketBeat recorded 3 mentions for Curis and 2 mentions for Cidara Therapeutics. Cidara Therapeutics' average media sentiment score of 1.44 beat Curis' score of 1.04 indicating that Cidara Therapeutics is being referred to more favorably in the news media.
Curis presently has a consensus price target of $37.33, indicating a potential upside of 243.45%. Cidara Therapeutics has a consensus price target of $4.67, indicating a potential upside of 407.25%. Given Cidara Therapeutics' higher probable upside, analysts plainly believe Cidara Therapeutics is more favorable than Curis.
Curis received 250 more outperform votes than Cidara Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Cidara Therapeutics an outperform vote while only 67.52% of users gave Curis an outperform vote.
30.0% of Curis shares are held by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are held by institutional investors. 4.8% of Curis shares are held by company insiders. Comparatively, 7.4% of Cidara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Cidara Therapeutics has higher revenue and earnings than Curis. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.
Curis has a beta of 3.76, meaning that its stock price is 276% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
Summary
Cidara Therapeutics beats Curis on 10 of the 16 factors compared between the two stocks.
Get Curis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools